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study shows that mere recommendation by CONITEC doesn’t guarantee access 
for the population in the timeframe established. Reasons should be investigated.
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Proceso De IncorPoracIón De Fármacos a La LIsTa PosITIva De 
meDIcamenTos (LPm) Para Los PresTaDores InTegraLes De saLuD: 
exPerIencIa en eL mInIsTerIo De saLuD PúbLIca (msP) De uruguay
Croci A, Deminco A, Villamil E, Alemán A, Pérez Galán A
Ministry of Public Health, Montevideo, Uruguay
Objectives: Describir el proceso para la de incorporación de fármacos al LPM en 
el marco del Sistema Nacional Integrado de Salud Uruguayo MethOds: El pro-
ceso comienza con la presentación de un formulario de solicitud al MSP al que se 
adjunta evidencia de alta calidad de su eficacia y seguridad comparado con las 
alternativas terapéuticas. Esta evidencia es analizada y complementada con una 
nueva búsqueda bibliográfica sistemática realizada por el evaluador. Se resumen 
los resultados de eficacia y seguridad obtenidos de estudios aleatorizados presen-
tados y cuando hay más de uno y es metodológicamente adecuado se realizan meta 
análisis. Si no hay estudios de comparación cabeza a cabeza se realizan en ocasiones 
comparaciones indirectas. Los informes de eficacia y seguridad son posteriormente 
evaluados por un experto clínico quienes aportan su punto de vista en cuanto a la 
pertinencia de la inclusión. Finalmente en los casos candidatos a ingresar se realiza 
un análisis económico (impacto presupuestal o estudios de costo utilidad según 
el precio del tratamiento anual sea menor o supere un PBI per cápita). Results: 
En 2011 solicitaron ingreso al FTM 123 fármacos, en 2012 fueron 37 fármacos, en 
2013 fueron 30 fármacos y en 2014 fueron 51 lo que totaliza 241 solicitudes. De 
estas, todos fueron completamente revisados, 54 fueron rechazados por insuficiente 
evidencia presentada, 163 tienen informes de eficacia y seguridad completos y 24 
están siendo evaluados en este sentido. De los 163 evaluados, 61 tienen pendientes 
evaluaciones clínica o económicas. cOnclusiOns: El desarrollo de un sistema de 
evaluación de tecnologías para informar a los decisores sobre la incorporación de 
nuevos fármacos a las listas positivas de medicamentos de los sistemas únicos de 
salud, requiere de tiempo y pericia técnica, pero es posible en entornos de recursos 
limitados y representa un avance con respecto a modalidades anteriores.
PaTIenT anD cLInIcIan PreFerences & QaLy sTuDIes
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Objectives: Clinical trials (CT) represent an important alternative treatment 
for oncologic patients. Also, CTs represent an important step to development of 
improved therapeutic strategies. On the other hand, little is known on Brazilian 
patient’s perception regarding CT. Therefore, the aim of this survey was to describe 
the overall perception of clinical research in Brazil. MethOds: From April 2012 
until October 2014, 254 respondents answered an internet-based survey related 
to knowledge related clinical research from Oncoguia Institute, an independent 
nonprofit cancer advocacy institution. Results: Overall, about 85% of respondents 
would participate on oncology trial. Of all respondents, 99.9% believe that clinical 
research can contribute positively to advance of cancer treatment by increasing 
the scientific knowledge, improvement of treatment, finding a cure, to have a new 
treatment option, or improved quality of life. Among the respondents, 96% affirmed 
that have already had some information on clinical research, being internet the 
most used form of communication (69%), followed by physicians´ orientation (8%), 
magazines and newspaper (8%) and hospital hand-out material (7%). In addition, 
only 18 respondents reported previously participation on CT (6.9%), and about 10% 
answered that have someone known that participated in a clinical trial (e.g. friend, 
family or other). cOnclusiOns: This survey demonstrates that respondents associ-
ate clinical research as an option in cancer treatment. However, only a small number 
of respondents have participated previously of a CT, besides that, internet was the 
main tool to learn about CTs. The data indicate that lack of available information, 
including low participation of physician on instructing their patients, are the current 
major barriers on CT in Brazil. Improvement of physician and patient awareness are 
potential solutions. Thus, strategies are needed to improve communication between 
patient and physician.
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Objectives: To derive a value set from Uruguayan general population using the 
new five level (5L) EQ-5D instrument and report population norms. MethOds: 
We randomly assigned general population individuals to value 10 health states 
using composite Time Trade Off and 7 pairs of health states through Discrete 
Choice Experiments. Additionally, respondent provided socidemographic infor-
mation and rated their current health state. The sample was stratified using with 
quotas by location, gender, age and socioeconomic status in order to represent 
the Uruguayan population structure. Trained interviewers conducted face to face 
interviews using EuroQol valuation technology (EQVT) to administer the protocol, 
as well as to collect and store the data. Primary analysis used OLS and maximum 
likelihood robust regression models with or without interactions Results: We 
included 794 respondents between 20 and 83 years. Their characteristics were 
in 2010, being the fourth main cause of death. WHO estimated the prevalence of DM 
in Brazil is 10.2%, about 20 million people. Objectives: To measure the DM social 
cost based in earnings losses of Brazilian workers due to disease in 2008 using 
data from National Survey of Households (PNAD/IBGE). MethOds: A Binary Probit 
model to measure the participation in work force and a two-stage Heckman model 
to measure worked hours and productivity. Each model is estimated separately 
for both gender individuals, with and without disease, according three distinct 
definitions for DM: Restrict, Broad and Comorbidities. To capture the counterfactual 
effect, the model was calculated for ill and healthy individuals. The difference of 
both values exhibited the losses, which were aggregate to the whole population and 
the total cost was estimated. Results: According each criterion, respectively, DM 
reduced the participation in the labor market in 0,97%; 4,60% and 7,06% for men 
and 0,14%; 4,79% and 6,44% for women, while reduced, respectively 1,51%; 6,40% 
and 9,15% in productivity and 6,44%; 15,23% and 17,58% in worked hours just for 
women. There was no impact of DM on productivity and in worked hours for men. 
The DM total cost was R$ 8,064 billion, or US$ 3,451 billion converted by current 
exchange rate. The losses reached 0,73% of total earnings and 0,27% of Brazilian 
GDP in 2008. cOnclusiOns: DM generates significant losses in income of Brazilian 
workers, especially in relation to their participation in the labor market, since affects 
both of gender. The results indicate that public policies should be directed to dis-
ease diagnosis and prevention, since the development of comorbidities amplifies 
the effect of losses.
HeaLTH TecHnoLogy assessmenT sTuDIes
HT1
raPID Increase oF HeaLTH LITIgaTIon as a means oF markeT access For 
InnovaTIve meDIcInes In coLombIa anD THe PoTenTIaL roLe oF HeaLTH 
TecHnoLogy assessmenT
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Objectives: Reimbursement of high-cost medicines excluded from the Colombian 
mandatory healthcare plan (POS) through legal mechanisms known as ‘tutela’ and 
the Scientific Technical Committees (CTC) have significantly increased in the last 
four years. As the new healthcare statutory law (1751-2015) puts pressure on the 
healthcare budget, it is likely that these will increase further. This research analy-
ses the “judicialisation” of the right to health in Colombia and the feasibility of a 
mandatory health technology assessment (HTA) evaluation as a policy to reduce 
reimbursement of non-POS medicines by litigation. MethOds: Secondary research 
of the main tutela decisions of the Colombian courts and CTC decisions related to 
non-POS medicines between 2011 and 2014 were conducted. A 2014 Ombudsman’s 
Office report of detailed medicine-tutelas was also analysed, and cross-referenced 
with statistics from the Colombian Ministry of Health and the General Prosecutor. 
A lack of official data for 2014 is addressed using case-by-case tutelas, literature 
review and stakeholder interviews. Results: Tutela and CTC decisions are pre-
dominantly in favour of protecting the fundamental right to health (80% of all deci-
sions between 2011 and 2014), giving access to non-POS medicines irrespective of 
cost-effectiveness. According to the Ombudsman’s Office, of the 115,147 tutelas 
presented in 2013, 34,099 (18.8%) were requests for medicines of which over half 
(22,685) were for access to non-POS medicine. The Colombian Fund of Solidarity and 
Guarantees paid health-promoting entities (EPS) over COP2 billion in 2012 and over 
2.5billion in 2013 for the reimbursement of non-POS medicines following tutela and 
CTC decisions. cOnclusiOns: Decisions over access to many high-cost medicines 
in Colombia are taken in courts based on infringement of fundamental rights rather 
than on cost and clinical-effectiveness assessments. This provides an important 
avenue to access new medicines, but also side-steps the formal reimbursement pro-
cess. A more systematic, binding HTA system would likely reduce health litigation.
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Objectives: Brazilian Federal Law 12.401/2011 created the National Committee 
for Health Technology Incorporation (CONITEC) and defined criteria and deadlines 
for health technology (HT) incorporation in public health system (SUS). CONITEC 
advises the Brazilian Ministry of Health about HT incorporation or disinvestment 
in SUS and clinical guidelines development. After CONITEC appraises and recom-
mends a technology, it should be available for the population in 180 days. The 
objective of this analysis was to evaluate the time between a technology was rec-
ommended by CONITEC and actually became available. MethOds: We reviewed 
all CONITEC’s reports since 2012, and selected those regarding drugs. Reports 
were classified in not recommended and recommended, and publication date was 
retrieved for those recommended. Simultaneously, we evaluated the date a drug 
recommended by CONITEC was received by the Centro de Medicamentos Básicos 
do Paraná (CEMEPAR), which is responsible for buying and distributing medica-
tions in Paraná. The time between report publication and drug availability was then 
assessed. Results: CONITEC published 125 reports since 2012, 93 on drugs and 42 
classified as recommended. These 42 represented 62 drugs with different pharma-
cologic concentrations. From these, it was the Paraná state’s liability to distribute 
45, which were then selected for the analysis. The majority of cases (64.4%) were in 
non-conformity with established deadlines: 55.5% were unavailable at CEMEPAR 
before 180 days, and 8.9% were never bought until the day of this analysis (February 
06th, 2015). The longest time between drug recommendation and its availability at 
CEMEPAR was 2 years and 73 days (salmeterol 50mcg) and the minimum was 13 
days (adalimumab 40mg). Average time for a drug to be available for distribution 
was 315.3 days (135.3 days beyond the established deadline). cOnclusiOns: This 
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standardized the oncology treatment fields available in the specific oncology data-
base (DataSUS AQ). Standardization included harmonization of different names 
used for the same drug name (i.e., cetuximab, cetux, cetukimabe and ketuxim), 
including generic and brand names. We also converted acronyms use in NCCN 
and MOC Brazil guidelines to the generic name (i.e.: fluoracil and 5FU; irinotecan 
and CPT-11). We created a new standardized table with additional fields (regimen 
name, drugs used, adjuvant therapy and a high/low cost flag). For this analysis we 
filtered by APAC (High complexity procedures approval) code for colorectal cancer 
(CRC) and lung cancer (LC) from 2012 to 2014. All blank or not identified regimens 
were excluded from this analysis. The final sample was composed by 50,729 CRC 
and 23,525 LC records. Results: It was compared the total number of regimens 
available at raw data and those standardized. Regarding CRC regimens we found 
7,698 different treatments in the raw database and 82 in the standardized dataset, 
a considerable reduction. In raw data, the most frequent regimen was FOLFOX rep-
resenting 7.9% of all records, in contrast to standardized dataset where FOLFOX 
regimen represented 33.6% of all records. We found 262 records written in differ-
ent ways in the raw database that referred to FOLFOX. Analyzing LC records, the 
most frequent regimen in raw data was carboplatin+taxo representing 3.1% of LC 
APACs claims in comparison to the standardized dataset where carboplatin+taxol 
represented 27.6% of all claims; 278 raw records had different names referring to 
carboplatin+taxol. cOnclusiOns: DataSUS can be a reliable source on oncology 
consumption therapies after standardizing data fields that were originally intro-
duced by manual typing.
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exTracTIng anD usIng DaTa From eLecTronIc meDIcaL recorDs (emr) 
To monITor QuaLITy oF care anD PrescrIPTIon PaTTerns For DIabeTes 
PrevenTIon anD conTroL In ouTPaTIenT cLInIcs oF Low anD mID 
resources counTrIes: THe case oF coLIma, mexIco
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Objectives: Evaluate the possibility of extracting data from the EMR used by 
the Health Services of Colima, Mexico and use it to assess the quality of care 
and prescription patterns for Diabetes prevention and control in outpatient clin-
ics. MethOds: A copy of the entire EMR database, including personal identifica-
tion variables, was obtained from the Health Services of Colima. A data verification 
and validation process was carried out including checking for EMR duplicity using 
Structured Query Language (SQL) and phonetic algorithms. A flat table for each 
patient’s encounter with the health services was constructed in order to have a 
longitudinal record along with vital signs, diagnostic and control tests as well as 
drugs prescribed. Each encounter was then coded to reflect in a single character 
string the main variables of diabetes care: number of visit after diagnosis, glucose 
measurement, drugs administered, as well as eye and feet examination. Results: 
The EMR in Colima initiated its operation in 2005 as a pilot in 3 clinics, in 2010 it 
covered about 50% of the state’s clinics (55) and in 2013 reached 100%: 117 clin-
ics. A total of 393,398 records were extracted and consolidated with 2,271,251 
outpatient visits in the period 2005 – march 2014. The age and sex structure of 
the population in the EMR was very similar to that of the 2010 population center 
for the state. Eleven percent of the population eighteen or older in the database 
was diagnosed with diabetes; only 45% of these had at least one glucose exam 
and only 16% were taking insulin. The most frequent medication prescribed was 
metformine. cOnclusiOns: The use of data from EMR is suitable to evaluate 
quality of care and prescription patterns in the prevention and control of diabetes 
mellitus. Continuing monitoring established quality parameters and prescription 
may help to improve quality.
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comParIson oF socIaL eQ-5D TIme TraDe-oFF vaLues In cHILe 2008-2013: 
Do geograPHIcaL DIFFerences reaLLy maTTer?
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Objectives: To evaluate differences in social values collected in the Chilean 
EQ-5D valuations surveys of 2008 and 2013 using the time trade-off method 
(TTO). MethOds: Responses from a total of 3701 individuals who participated in 
the 2008 and 2013 Chilean EQ-5D valuation surveys were analyzed to assess dif-
ferences in TTO values from 31 health states between both studies adjusting for 
gender, age and educational attendance. Differences were explored using several 
ordinary least square (OLS) regression models taking into account sampling weights. 
Variations of TTO values between the Metropolitan Region (MR) and the rest of the 
country were evaluated using data only from the 2013 survey adjusting not only 
for socio-demographic characteristics, but also for other variables known to have 
an effect on respondent´s values such as self-reported health status, marital status 
and level of difficulty answering the TTO questionnaire. Results: A basic regres-
sion model showed significant differences (p value < 0.001) between both surveys 
indicating that 2008´s TTO values collected only in the MR were lower than 2013´s 
TTO values collected alongside the whole country. These differences remain after 
adjusting for confounding variables. Exploring possible determinants of geographi-
cal differences at individual level based on 2013 data, only years of education and 
a high level of difficulty answering the TTO questionnaire appeared to have a sig-
nificant effect on valuations (p value < 0.001). However, those effects were marginal 
and do not fully explain the differences found between TTO values collected in the 
MR and the rest of the country. cOnclusiOns: Our findings support the idea that 
cultural/geographical differences could have a significant impact on social values 
within-country. These differences constitute an important factor that should be 
taken into consideration when designing and analyzing results from these types 
of studies on a national level. Further international research is required to improve 
knowledge on this topic.
broadly similar to the Uruguayan population. Forty four percent of the subjects 
reported no problems on any of the five EQ-5D-5L dimensions. Older respondents 
reported more problems in all dimensions. Mean self-reported VAS was 79.63 
(SE 0.58); it decreased with age and was lower in women. As OLS model showed 
logical inconsistencies, robust modelling was chosen to derive social values. 
Values ranged from -0.264 to 1. States with a misery index= 6 had a mean value 
of 0.965. When comparing the prediction for a misery index= 6 in the Uruguayan 
population with the Argentinian EQ-5D-5L crosswalk value set, the Uruguay val-
ues are about 0.05 higher. The mean index value for the general population in 
Uruguay, using the final main effects Uruguayan EQ-5D-5L value set, is 0.895. In 
general, older people had worse values and males had slightly better values than 
females. cOnclusiOns: We derived the EQ-5D-5L Uruguayan value set, the first 
in Latin America. These results will help inform decision-making using economic 
evaluations for resource allocation decisions.
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Objectives: The aim of this study is to estimate the cost-effectiveness of cervical 
cancer primary screening with HPV PCR tests in Brazil. MethOds: A Markov model 
captured the outcomes of 1,000 non-hysterectomized women ages 25 years and 
older who transitioned annually across possible health states and were screened 
over a 45-year period in Brazil. This model was used to compare three strategies: 
(1) cytology alone (2) Pooled HPV with reflex cytology (3) HPV with 16/18 genotyping 
and reflex cytology, from a payer’s perspective. The one-way and probabilistic sen-
sitivity analyses were performed. Additionally, the screening and cancer treatment 
costs were calculated according to DATASUS 2012 (Departamento de Informática do 
Sistema Único de Saúde - Brazil) public data, in Brazilian Real (BRL) and discounted 
at an annual rate of 5%. Results: The primary screening with the strategy (3) HPV 
with 16/18 genotyping and reflex cytology, results in earlier detection of clinically 
relevant high-grade CIN (Cervical Intraepithelial Neoplasia) at the initial visit along 
with efficient use of healthcare resource in Brazil. In addition, the model suggested 
an Incremental Cost Utility Ratio (ICUR) and Incremental Cost Effectiveness Ratio 
(ICER) of 13,266 R$/QALY and 51,389 R$/LYG, respectively, comparing the strategies 
(3) to (1), whereas, the strategy (2) was dominated by strategy (3). cOnclusiOns: 
The current analysis indicated that the HPV with 16/18 genotyping test (strategy 3) 
is cost-effective for primary cervical cancer screening in women aged ≥ 25 years in 
Brazil due to the ICER ≤ 3 Brazilian GDP per capita, according to the World Health 
Organization’s recommendations.
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Objectives: Health Technology Appraisal processes in Latin American countries 
are of increasing importance. For decisions made on the basis of cost per qual-
ity-adjusted life year, the utility inputs used in the economic model are typically 
influential on the outcome. Utility valuations vary from country to country and we 
therefore sought to review the availability of valuations for Latin American coun-
tries. MethOds: Using PubMed, a structured search was conducted to identify 
which of the common generic, preference-based instruments had valuations for 
Latin American countries. The instruments included in the search were EQ-5D, 
SF-6D and HUI. Identified studies were retrieved in full text and, where extant, 
valuations of each instrument across different countries were compared. Results: 
The review identified no HUI valuations, one SF-6D valuation (in Brazil) and three 
EQ-5D valuations (in Argentina, Chile and Brazil). The three EQ-5D valuations all 
used time trade-off methodology but the sampled states used differed such that 
only 13 states had an observed value across all three studies. Visual comparison 
of these observed states revealed considerable divergence of the Chilean valuation 
from the Brazilian and Argentinian valuations in the lower health states. This trend 
remained when the final modelled values for the full set of EQ-5D health states were 
plotted. Divergence increased in worse states, producing greater utility differences 
between states in Chile. cOnclusiOns: There are currently a limited number of 
valuation sets available in Latin America. Only EQ-5D has multiple valuations to 
allow inter-country comparison, revealing clear differences. Such noticeable varia-
tions between countries in the value of changing health states make it unlikely that 
cost-utility analyses are generalisable in the region, affecting pricing and reimburse-
ment decisions. Further work therefore remains to generate valuation sets for other 
countries in Latin America to allow an understanding of how reimbursement may 
be affected by increasing use of HTA.
researcH on meTHoDs sTuDIes
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sysTem: a comParIson beTween raw anD sTanDarDIzeD DaTaseT In 
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Objectives: To compare results of oncology drugs consumption extracted from 
DataSUS raw database with those obtained after standardizing and cleaning data-
base fields. MethOds: We used the SUS database available from DataSUS FTP and 
